The emerging role of complement in neuromuscular disorders

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• The complement cascade is a crucial immune system component involved in host defense against pathogens and damaged cells.
• Recent successes in complement inhibitor clinical trials have revitalized interest in targeting this pathway for therapeutic benefit.
• Emerging evidence highlights the significant role of complement activation in the pathology of various neuromuscular disorders.

Purpose of the Study:

• To provide a comprehensive review of complement activation in neuromuscular diseases.
• To explore the role of complement in the initiation and progression of myasthenia gravis, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy.
• To summarize preclinical and clinical evidence supporting complement-targeting therapies for these conditions.

Main Methods:

• Literature review of preclinical studies.
• Analysis of clinical trial data for complement inhibitors.
• Synthesis of evidence linking complement activation to neuromuscular disease pathology.

Main Results:

• Demonstrated links between complement activation and disease progression in myasthenia gravis, ALS, and Duchenne muscular dystrophy.
• Preclinical and clinical data support the therapeutic potential of targeting the complement system.
• Several complement-targeting drugs are currently in clinical trials for these neuromuscular indications.

Conclusions:

• Complement activation is a key factor in the pathogenesis of several neuromuscular diseases.
• Targeting the complement cascade represents a promising therapeutic strategy for preventing tissue destruction in these disorders.
• Ongoing clinical trials are evaluating the efficacy of complement inhibitors for myasthenia gravis, ALS, and Duchenne muscular dystrophy.